Septerna (NASDAQ:SEPN) Shares Up 7.9% – Still a Buy?

Septerna, Inc. (NASDAQ:SEPN) was up 7.9% during trading on Monday . The stock traded as high as $25.50 and last traded at $25.18. Approximately 78,211 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 278,571 shares. The stock had previously closed at $23.34.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Raymond James Financial initiated coverage on Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target for the company. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $18.00 to $28.00 in a research note on Friday, November 14th. Zacks Research downgraded Septerna from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Finally, Jones Trading started coverage on shares of Septerna in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.83.

Septerna Stock Up 6.4%

The stock’s 50 day moving average is $26.89 and its 200-day moving average is $20.31. The company has a market cap of $1.11 billion, a PE ratio of -16.45 and a beta of 3.86.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. On average, analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Insider Activity at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the transaction, the senior vice president directly owned 92,911 shares in the company, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Woodline Partners LP lifted its stake in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after acquiring an additional 282,585 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after purchasing an additional 3,323 shares during the last quarter. Geode Capital Management LLC increased its stake in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock worth $5,158,000 after buying an additional 78,316 shares during the period. Intech Investment Management LLC bought a new stake in Septerna during the 2nd quarter valued at about $129,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Septerna by 116.7% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock valued at $2,354,000 after buying an additional 119,953 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.